Todd Korthuis, M.D., M.P.H.
- Professor of Medicine, School of Medicine
- Chief, Addiction Medicine Section
- Program Director, Addiction Medicine Fellowship
Biography
Todd Korthuis is a general internist, addiction medicine specialist, and clinician scientist. He began his clinical career treating patients living with HIV and has practiced addiction medicine since 2004. He serves as Head of the Section of Addiction Medicine at OHSU. His research focuses on integration of addiction treatment and prevention in diverse health care settings. He serves as Co-Principal Investigator of the National Drug Abuse Treatment Clinical Trials Network (CTN) Western States Node that tests new treatment strategies for opioid, methamphetamine, and cocaine use disorders (UG1DA015815). He has served as Principal Investigator for multiple NIH-funded research studies including the CTN-0067 trial of extended-release naltrexone in North American HIV clinics, the BRAVO implementation trial of buprenorphine for OUD in Vietnam HIV clinics, the Oregon HOPE peer engagement intervention to decrease overdose in rural Oregon, and the PROUD-R2 peer intervention to improve retention of people who use drugs in clinical trials in rural America. Honors include the 2008 Lawrence S. Linn Award for research that improves the lives of people living with HIV, a 2012-2013 Fulbright Scholar award to study integration of HIV and addiction care in Vietnam, and a 2022 Fulbright Senior Scholar Award to study the intersection of harm reduction and substance use disorder treatment in Barcelona, Spain.
A complete list of Dr. Korthuis' publications is available in MyBibliography.
Education and training
-
Degrees
- B.S., 1986, Azusa Pacific University
- M.D., 1991, University of Health Sciences/Chicago Medical School
- M.P.H., 2002, University of California Los Angeles
-
Internship
- Naval Medical Center San Diego, 1991-1992
-
Residency
- Yale University School of Medicine, 1996-1998
- Yale University School of Medicine, 1998-1999
-
Fellowship
- West Los Angeles Veterans Administration Ambulatory Care, 2000-2002
-
Certifications
- American Board of Preventive Medicine, Addiction Medicine Subspecialty, 2019-current
- American Board of Addiction Medicine, 2010-current
- American Board of Internal Medicine, 1998-current
Memberships and associations:
- Society of General Internal Medicine
Areas of interest
- Addiction Medicine
- HIV
- General Internal Medicine
Publications
Elsevier pure profileSelected publications
- Kohno M, Dennis LE, McCready H, Schwartz DL, Hoffman WF, Korthuis PT. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend. 2018;192:186-192. PMC6200637
- Springer SA, , Korthuis PT, Del Rio C. Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. Ann. Intern. Med. 2018;169(5):335-336. PMC6251491
- McCarty D, Priest K, Korthuis PT. Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. Annu. Rev. Public Health. 2018;39:525-541. PMC5880741
- Korthuis PT, Edelman EJ. Substance use and the HIV care continuum: important advances. Addict Sci Clin Pract, 2018. 13(1): p. 13. PMC5848588
- Chou R, Korthuis PT, McCarty D, Coffin PO, Griffin JC, Davis-O'Reilly C, Grusing S, Daya M. Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings: A Systematic Review. Ann Intern Med 2017; 167(12):867-75.
- Korthuis PT, McCarty D, Weimer D, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, Chou R. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Annals of Internal Medicine. 2017; 166 (4):268-278. PMC 5504692.
- Englander H, Weimer M, Solotaroff R, Nicolaidis C, Chan B, Velez C, Noice A, Hartnett T, Blackburn E, Barnes P, Korthuis PT. Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder. Journal of Hospital Medicine (2017); 12(5):339-342. PMC5542562
- Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, Oden NL, Lindblad R, Sorensen JL, Arenas V, Ha D, Mandler RD, McCarty D for the CTN-0055 CHOICES Investigators. "Feasibility and Safety of Extended-Release Naltrexone Treatment of Opioid and Alcohol Use Disorder in HIV Clinics: A Pilot/Feasibility Randomized Trial." Addiction 2017; (6): 1036-1044. PMC 5408318.
- Nguyen Bich D, Korthuis PT, Nguyen Thu T, Van Dinh H, Le Minh G. HIV patients' preference for integrated models of addiction and HIV treatment in Vietnam. J Substance Abuse Treat 2016 (69): 57–63. PMC5517304.
- Callon W, Beach MC, Saha S, Chander G, Wilson IB, Laws MB, Sharp V, Cohn J, Moore RD, Korthuis PT. Assessing Problematic Substance Use in HIV Care: Which Questions Elicit Accurate Patient Disclosures? Journal of General Internal Medicine, 2016. 31(10): 1141-7. PMC5023601